drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
== Method == A model resonance ionization mass spectrometry (RIMS) set-up consists of a laser system (consisting of multiple lasers), sample from which the atoms are derived, and a suitable mass spectrometer which mass-selectively detects the photo ions created from resonance. In resonant ionization, atoms or molecules from ground state are excited to higher energy states by the resonant absorption of photons to produce ions. These ions are then monitored by appropriate detectors. In order to ensure a highly-efficient sensitivity and process saturation, the atomic or molecular beam must be formed from the ground state, the atoms should be efficiently excited and ionized, and each atom should be converted by the photon field of a short-timed pulsed laser to produce a positive ion and a valence electron. In a basic RIS process, a pulsed laser beam produces photons of the right energy in order to excite an atom initially in its ground state, a, to an excited level, b. During the laser pulse, the ion population of state b increases at the expense of that of state a. After a few minutes, the rate of stimulated emission from the excited state will equal rate of production so that the system is in equilibrium as long as the laser intensity is kept sufficiently high during a pulse. This high laser intensity translates into a photon fluence (photons per unit of beam area) large enough so that a necessary condition for the saturation of the RIS process has been met.
This was also the belief of geologist Palmer, who convinced Steven Jones that the helium-3 occurring naturally in Earth perhaps came from fusion involving hydrogen isotopes inside catalysts like nickel and palladium. This led their team in 1986 to independently make the same experimental setup as Fleischmann and Pons (a palladium cathode submerged in heavy water, absorbing deuterium via electrolysis). Fleischmann and Pons had much the same belief, but they calculated the pressure to be of 1027 atmospheres, when cold fusion experiments achieve a loading ratio of only one to one, which has only between 10,000 and 20,000 atmospheres. John R. Huizenga says they had misinterpreted the Nernst equation, leading them to believe that there was enough pressure to bring deuterons so close to each other that there would be spontaneous fusions.
When cultivated for human consumption in Western nations, insects are held to the same safety requirements as any other food. Depending on the popularity in a given location, processing might be done commercially or locally. The procedure begins with the removal of the insect's insides, albeit this step is optional. They are then dispatched to be preserved or freeze-dried, which is accomplished using hessian or polypropylene. They are transported for storage once they have been entirely preserved/dried. Insects can be frozen or ground into powders. Cricket flour is produced from freeze-dried crickets. The crickets are then cooked to facilitate processing. They are pulverized into extremely fine bits after being cooked. The freezing, baking, and drying results in a powdered dark brown flour. Insect flour is one of Whole Foods Market's banned ingredients in the U.S., with cricket flour being specifically mentioned on their paper bags.
== Development and spread of the Tiselius apparatus == The apparatus designed by Arne Tiselius in 1931 enabled a range of new applications of electrophoresis in analyzing chemical mixtures. Its development, significantly funded by the Rockefeller Foundation, was an extension of Tiselius' earlier PhD studies. With more assistance from the Rockefeller Foundation, the expensive Tiselius apparatus was built at a number of major centers of chemical research.
Sources: en.wikipedia.org
== Function == This gene encodes the insulin receptor substrate 2, a cytoplasmic signaling molecule that mediates effects of insulin, insulin-like growth factor 1, and other cytokines by acting as a molecular adaptor between diverse receptor tyrosine kinases and downstream effectors. The product of this gene is phosphorylated by the insulin receptor tyrosine kinase upon receptor stimulation, as well as by an interleukin 4 receptor-associated kinase in response to IL4 treatment. Mice lacking IRS2 have a diabetic phenotype as well as a 40% reduction in brain mass.
To provide a deeper scientific foundation for MD students, Einstein hosts the five-year Clinical Research Training Program (CRTP). The CRTP confers a Master of Science and requires an additional year of courses on clinical research methods. Students may also graduate with distinction in research for their medical degree. With Yeshiva's Benjamin N. Cardozo School of Law, Einstein offers both a certificate and Master of Science in Bioethics. The program covers clinical bioethics consultation, healthcare ethics policy, and human subject research. Einstein also offers MD students a joint Master of Public Health degree with the City University of New York (CUNY). This Einstein-CUNY MD-MPH program lasts five years.
=== Phase 3 === Benzoyl peroxide/tretinoin (IDP-120) – combination of benzoyl peroxide (undefined mechanism of action) and tretinoin (retinoid) Berdazimer sodium (SB-204; MAP3-NONOate; NVN1000) – nitric oxide releasing agent Denifanstat (ASC–40; TVB-2640) – fatty acid synthetase complex inhibitor GED 0507-34-Levo (GED-0507; GED-0507-34; N-acetyl-GED-0507-34; NAC-GED-0507) – peroxisome proliferator-activated receptor gamma (PPARγ) modulator
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.